Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sanofi-aventis to Maintain Same Volume of Sales in 2010: Dr Chocat
December 14, 2009
- GSK Files for Rotavirus Vaccine Rotarix
December 14, 2009
- DSP to Spin Off Animal Health, Food & Speciality Products
December 14, 2009
- FDA Advisory Committee Supports Safety, Efficacy of Prevnar 13
December 14, 2009
- EFPIA Japan Appoints Masuhiro Kato Chairman
December 14, 2009
- More Than 60% of Patients Dissatisfied with Existing Oral Hypoglycemic Agents
December 14, 2009
- No New Safety Measures Required for Lantus: PMDA
December 14, 2009
- GRU's WG Demands Reductions in METI's Budgets for Drug Discovery Research
December 14, 2009
- Korosho Decides How to Respond to GRU's Recommendations
December 14, 2009
- 2-Year Extension OK'd for R&D Tax Breaks for Both Increased and High-Level Investment
December 14, 2009
- Merck Serono Aims to Launch Cancer Vaccine by 2015
December 14, 2009
- Takara Bio Begins PI Trial for Gene Therapy for Relapsed Leukemia
December 14, 2009
- Industry-Proposed Price Maintenance System Meets No Strong Opposition at Chuikyo
December 14, 2009
- Crestor Reduces CV Events Risk in Women by 46%
December 14, 2009
- A Ray of Light for Industry's Proposal?
December 14, 2009
- Actemra Improves sJIA in Children: Roche, Chugai
December 14, 2009
- Key Points at Issue Listed by Korosho for Discussions on Drug Pricing System Reform
December 14, 2009
- Protein-Mall Kansai Expands Membership
December 14, 2009
- Parliamentary Secretary of Health Objects to GRU Recommendations
December 14, 2009
- Eisai Launches New Oral Jelly Formulation of Aricept
December 14, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…